Table 6.

Dynamics of overall monthly changes in total values from individual symptoms determined according to Kupperman’s Menopausal Index (KMI) and Greene’s Menopausal Score (GMS) recorded between Admission point (A), at four monthly sampling points (Month Model)^a and Placebo (P) versus Maca-GO (M) contrast (Treatment Model) according to two sequences of Maca-GO application (pre- and post Placebo) during four month of crossover Trial (n=22)

Treatment	Admission A	After Month 1 P	After Month 2 P	After Month 3 M	After Month 4 M	SEDb	Placebo	Maca	SED	Pc
Kupperman’s Menopausal Index (KMI)
OPPMM	30.40	15.20	24.00	10.80	6.99	1.69	19.60	9.65	1.31	<0.001
OMMPP	29.64	13.09	9.45	14.88	19.58	1.52	17.21	11.27	1.30	<0.001
SED		3.52	3.52	3.53	3.59		3.47	3.47
Greene’s Menopausal Score (GMS)
OPPMM	25.80	10.90	8.60	8.90	3.30	1.55	9.75	6.10	1.44	<0.01
OMMPP	30.91	12.45	10.91	13.00	7.18	1.48	10.09	11.68	1.37	ns
SED		4.28	4.28	4.28	4.28		4.35	4.04

^aFor explanation see Table 1;

^bSED, Standard error of differences;

^cP, Probabilities of significance. ns, not significant at P>0.05; <0.05, significance at 5% probability level; <0.01, significance at 1% probability level; <0.001, significance at 0.1% probability level.